Last reviewed · How we verify
Sorafenib Tosylate Tablets
Sorafenib Tosylate Tablets inhibit multiple intracellular and cell surface kinases, which are involved in tumor growth and angiogenesis.
Sorafenib Tosylate Tablets inhibit multiple intracellular and cell surface kinases, which are involved in tumor growth and angiogenesis. Used for Advanced renal cell carcinoma, Advanced hepatocellular carcinoma, Advanced radioactive iodine-refractory differentiated thyroid cancer.
At a glance
| Generic name | Sorafenib Tosylate Tablets |
|---|---|
| Also known as | Nexavar |
| Sponsor | Beijing Shenogen Biomedical Co., Ltd |
| Drug class | multi-kinase inhibitor |
| Target | RAF kinase, VEGFR, PDGFR |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Sorafenib Tosylate Tablets work by targeting various kinases, including RAF kinase, VEGFR, and PDGFR, which play a role in tumor growth and angiogenesis. This leads to the inhibition of tumor cell proliferation and the induction of apoptosis. Additionally, sorafenib tosylate tablets may also have anti-angiogenic effects by inhibiting the formation of new blood vessels that supply the tumor.
Approved indications
- Advanced renal cell carcinoma
- Advanced hepatocellular carcinoma
- Advanced radioactive iodine-refractory differentiated thyroid cancer
Common side effects
- Fatigue
- Diarrhea
- Hand-foot skin reaction
- Hypertension
- Dermatological reactions
- Thrombocytopenia
- Anemia
- Neutropenia
- Leukopenia
- Anorexia
Key clinical trials
- A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC) (PHASE3)
- The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma Subjects (PHASE3)
- AflacLL1901 (CHOA-AML) (PHASE2)
- QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine (PHASE1, PHASE2)
- Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients With Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed By Surgery (PHASE1)
- External-Beam Radiation Therapy, Capecitabine, and Sorafenib in Treating Patients With Locally Advanced Rectal Cancer (PHASE1, PHASE2)
- Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (PHASE1, PHASE2)
- Study to Compare Selective Internal Radiation Therapy (SIRT) Versus Sorafenib in Locally Advanced Hepatocellular Carcinoma (HCC) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sorafenib Tosylate Tablets CI brief — competitive landscape report
- Sorafenib Tosylate Tablets updates RSS · CI watch RSS
- Beijing Shenogen Biomedical Co., Ltd portfolio CI